# 2026年2月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 对“DESTINY-Lung02研究的最终分析结果及患者报告结果——德曲妥珠单抗在HER2突变型转移性非小细胞肺癌患者中进行的剂量盲态、随机、2期研究”的更正 [Journal of Thoracic Oncology 第20卷 第12期 (2025) 1814-1828]。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41729148)
**期刊：** Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
**PMID：** 41729148
**DOI：** 10.1016/j.jtho.2026.103557

### 第一部分 原文与翻译

**英文原标题：** Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文献是针对DESTINY-Lung02研究最终分析结果及患者报告结局报告的勘误说明。该原始研究是一项关键的2期临床试验，确立了德曲妥珠单抗（T-DXd）在HER2突变转移性非小细胞肺癌患者中的治疗地位。此类勘误文件的发布体现了国际胸部肿瘤研究协会（IASLC）官刊对于临床数据准确性的高度严谨态度，确保了该重要临床证据在学术引用中的精确性。虽然不含核心研究数据，但对于完整理解DESTINY-Lung02研究的最终结论具有补充价值。

---

## 2. 高通量中和测定与人类流感毒株的进化成功密切相关

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41725518)
**期刊：** eLife
**PMID：** 41725518
**DOI：** 10.7554/eLife.106811

### 第一部分 原文与翻译

**英文原标题：** High-throughput neutralization measurements correlate strongly with evolutionary success of human influenza strains.

> **英文摘要：**
> Human influenza viruses rapidly acquire mutations in their hemagglutinin (HA) protein that erode neutralization by antibodies from prior exposures. Here, we use a sequencing-based assay to measure neutralization titers for 78 recent H3N2 HA strains against a large set of children and adult sera, measuring ~10,000 total titers. There is substantial person-to-person heterogeneity in the titers against different viral strains, both within and across age cohorts. The growth rates of H3N2 strains in the human population in 2023 are highly correlated with the fraction of sera with low titers against each strain. Notably, strain growth rates are less correlated with neutralization titers against pools of human sera, demonstrating the importance of population heterogeneity in shaping viral evolution. Overall, these results suggest that high-throughput neutralization measurements of human sera against many different viral strains can help explain the evolution of human influenza.

> **中文摘要：**
> 人类流感病毒在其血凝素（HA）蛋白中迅速积累突变，从而削弱了先前暴露产生的抗体的中和作用。在本研究中，我们使用一种基于测序的检测方法，测量了78种近期H3N2 HA毒株对大量儿童和成人血清的中和效价，共计测量了约10,000个效价。在针对不同病毒株的效价方面，无论是在年龄组内还是跨年龄组，都存在显著的个体间异质性。2023年H3N2毒株在人群中的增长率与对每种毒株具有低效价的血清比例高度相关。值得注意的是，毒株增长率与针对混合人血清的中和效价相关性较低，这证明了人群异质性在塑造病毒进化中的重要性。总之，这些结果表明，针对多种不同病毒株的人血清高通量中和测量有助于解释人类流感的进化。

### 第二部分 AI 大师评价

该研究利用创新的基于测序的高通量检测技术，系统性地评估了H3N2流感病毒株在人群中的免疫逃逸与进化的关系。核心发现指出，病毒在人群中的进化成功（增长率）与低中和效价个体的比例密切相关，而非传统的群体平均效价，凸显了人群免疫异质性在预测流感进化方向中的关键地位。这一成果为未来流感病毒的监测和疫苗株预测提供了更精准的量化分析框架，具有重要的公共卫生应用价值。

---

## 3. 起源细胞与遗传驱动因素定义了小鼠模型中晚期膀胱癌的亚型及潜在治疗反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41724981)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41724981
**DOI：** 10.1186/s13046-026-03677-8

### 第一部分 原文与翻译

**英文原标题：** Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无可用摘要。

### 第二部分 AI 大师评价

该研究利用小鼠模型，深入探讨了起源细胞与遗传驱动因素如何共同决定晚期膀胱癌的特定亚型。通过揭示不同亚型在分子层面的异质性，研究进一步阐述了这些生物学特性如何影响其对临床潜在治疗方案的反应。该成果为膀胱癌的精准分型提供了关键的理论依据，对开发针对特定亚型的个性化治疗策略具有重要的参考价值。

---

## 4. UVI5008：首个用于治疗B细胞恶性肿瘤的可逆、非共价布鲁顿酪氨酸激酶（BTK）表观抑制剂

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41724980)
**期刊：** Journal of hematology & oncology
**PMID：** 41724980
**DOI：** 10.1186/s13045-026-01784-9

### 第一部分 原文与翻译

**英文原标题：** UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

> **英文摘要：**
> BACKGROUND: Chronic lymphocytic leukemia (CLL) can still be a therapeutic challenge; notwithstanding substantial progress in therapeutic approaches with small molecule inhibitors, the emergence of inhibitor resistance and suboptimal long-term outcomes highlight the persistent need for novel, more effective treatment strategies, especially targeting resistance. PATIENTS AND METHODS: Kinase activity screening was performed on UVI5008, followed by computational study. The findings were validated through a comprehensive set of in vitro and ex vivo assays, including enzymatic, cellular, transcriptional, genetic, epigenetic, and genomic assays, on primary CLL patient-derived peripheral blood mononuclear cells and cell lines, as well as through in vivo studies using genetically engineered mouse models. RESULTS: We identified a novel tyrosine kinase inhibitory activity of UVI5008, currently the only known epigenetic modulator (epi-inhibitor) that directly targets Bruton's tyrosine kinase (BTK), affecting both BTK expression and enzymatic function. Our comprehensive analysis, combining in silico, ex vivo, and in vivo approaches, revealed that UVI5008 effectively inhibits both wild-type BTK and the C481S mutated BTK isoform, commonly associated with BTK-inhibitor resistance in CLL. Treatment with UVI5008 in B-cell lymphoma and leukemia disorders led to a substantial increase in cellular apoptosis, accompanied by a notable reduction in phosphorylation and BTK protein levels, as well as attenuation of downstream signaling, thus demonstrating superior efficacy compared to ibrutinib. Ex vivo treatment of patient-derived CLL samples and in vivo murine models corroborated these results, further supporting the potential of UVI5008 as a promising therapeutic agent. CONCLUSION: UVI5008 represents a promising pharmacological alternative to current BTK inhibitors. As the first-in-class, non-covalent, reversible, BTK inhibitor and epi-inhibitor of expression. UV15008 demonstrates potent in vitro anti-tumor efficacy in relapsed/refractory CLL cells, including cases with the C481S BTK mutation and in in vivo animal studies.

> **中文摘要：**
> 背景：慢性淋巴细胞白血病（CLL）目前仍是一项治疗挑战；尽管在小分子抑制剂的治疗方法上取得了实质性进展，但抑制剂耐药性的出现和不理想的长期预后凸显了对新型、更有效治疗策略（尤其是针对耐药性）的持续需求。患者与方法：对UVI5008进行了激酶活性筛选，随后进行了计算研究。通过对原代CLL患者来源的外周血单个核细胞和细胞系进行的一系列全面的体外和离体实验（包括酶学、细胞、转录、遗传、表观遗传和基因组分析），以及利用基因工程小鼠模型进行的体内研究，验证了上述发现。结果：我们发现了UVI5008的一种新型酪氨酸激酶抑制活性，它是目前唯一已知的直接靶向布鲁顿酪氨酸激酶（BTK）的表观遗传调节剂（表观抑制剂），能够同时影响BTK的表达和酶功能。我们的综合分析（结合了计算机模拟、离体和体内方法）表明，UVI5008能有效抑制野生型BTK和C481S突变型BTK异构体，后者通常与CLL中的BTK抑制剂耐药性相关。在B细胞淋巴瘤和白血病疾病中，UVI5008治疗导致细胞凋亡显著增加，伴随着磷酸化水平和BTK蛋白水平的显著降低，以及下游信号传导的减弱，从而证明了其优于伊布替尼的疗效。对患者来源CLL样本的离体治疗和体内小鼠模型证实了这些结果，进一步支持了UVI5008作为一种极具前景的治疗药物的潜力。结论：UVI5008代表了现有BTK抑制剂的一种有希望的药理学替代方案。作为首创的非共价、可逆BTK抑制剂和表达表观抑制剂，UVI5008在复发/难治性CLL细胞（包括携带C481S BTK突变的病例）以及体内动物研究中表现出强大的抗肿瘤效力。

### 第二部分 AI 大师评价

本研究介绍了一种名为UVI5008的创新型双重机制药物，它是首个集成了BTK酶活性抑制与表观遗传表达调控功能的可逆、非共价抑制剂。研究通过多维度实验证明，UVI5008不仅能有效克服伊布替尼常见的C481S耐药突变，还在下调BTK蛋白水平和诱导凋亡方面表现出优于传统抑制剂的效果。该分子的独特性在于其“表观抑制剂”的双重属性，为复发/难治性B细胞恶性肿瘤提供了一种突破性的治疗策略，具有极高的临床转化潜力。

---

## 5. PRDM1通过抑制OTUD6A介导的CDC6去泛素化，限制膀胱癌进展并增强化学敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41724787)
**期刊：** Cell death & disease
**PMID：** 41724787
**DOI：** 10.1038/s41419-026-08498-3

### 第一部分 原文与翻译

**英文原标题：** PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.

> **英文摘要：**
> PR domain zinc finger protein 1 (PRDM1) functions as a critical transcriptional repressor. The role of PRDM1 in various tumors is controversial, and its specific mechanism in bladder cancer (BCa) remains unclear. In the present study, we demonstrated that PRDM1 expression is downregulated in both human BCa tissues and BBN-induced mouse models of BCa. Gain- and loss-of-function experiments revealed that PRDM1 delays cell cycle progression, suppresses BCa cell proliferation, and enhances chemosensitivity, whereas PRDM1 knockdown promotes cell proliferation and induces chemoresistance. Ovarian tumor deubiquitinase 6 A (OTUD6A) is a deubiquitinating enzyme that prevents the proteasomal degradation of CDC6. PRDM1 directly binds to the OTUD6A promoter and suppresses its transcription, thereby reducing CDC6 deubiquitination and promoting its degradation. Knockdown of CDC6 or OTUD6A abrogates the protective effects of PRDM1 both in vitro and in vivo. Consistently, PRDM1 expression is negatively correlated with CDC6 and OTUD6A expression in BCa tissues. Collectively, these findings demonstrate that PRDM1 acts as a tumor suppressor in BCa by inhibiting OTUD6A transcription and promoting CDC6 degradation. We propose a PRDM1‒OTUD6A‒CDC6 axis model, providing novel insights into PRDM1 as a potential therapeutic target in BCa.

> **中文摘要：**
> PR结构域锌指蛋白1 (PRDM1) 是一种关键的转录阻遏因子。PRDM1在各种肿瘤中的作用存在争议，其在膀胱癌 (BCa) 中的具体机制尚不清楚。在本研究中，我们证明了PRDM1在人类BCa组织和BBN诱导的BCa小鼠模型中表达均下调。功能获得和缺失实验表明，PRDM1可延迟细胞周期进程、抑制BCa细胞增殖并增强化学敏感性，而敲低PRDM1则会促进细胞增殖并诱导化疗耐药。卵巢肿瘤去泛素化酶6 A (OTUD6A) 是一种去泛素化酶，能够防止CDC6发生蛋白酶体降解。PRDM1直接结合OTUD6A启动子并抑制其转录，从而减少CDC6的去泛素化并促进其降解。敲低CDC6或OTUD6A在体内外实验中均能消除PRDM1的保护作用。一致的是，在BCa组织中，PRDM1的表达与CDC6和OTUD6A的表达呈负相关。总的来说，这些研究结果表明，PRDM1通过抑制OTUD6A转录并促进CDC6降解，在BCa中发挥抑癌基因的作用。我们提出了PRDM1-OTUD6A-CDC6轴模型，为PRDM1作为BCa潜在治疗靶点提供了新的见解。

### 第二部分 AI 大师评价

本研究揭示了PRDM1在膀胱癌中的抑癌作用及其精细的分子机制，即通过作为转录阻遏物抑制OTUD6A的表达，进而促进关键复制因子CDC6的降解。研究通过临床样本、小鼠模型和细胞实验构建了完整的PRDM1-OTUD6A-CDC6调控轴，逻辑严密且证据链充分。其创新性在于将转录调控与蛋白质去泛素化修饰相结合，为克服膀胱癌的化疗耐药性提供了新的治疗思路及潜在的分子靶点。

---

## 6. 癌症神经科学：癌症的信号通路与新治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41724757)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41724757
**DOI：** 10.1038/s41392-025-02364-y

### 第一部分 原文与翻译

**英文原标题：** Cancer neuroscience: signaling pathways and new therapeutic strategies for cancer.

> **英文摘要：**
> From a neuroscience perspective, cancer neuroscience has emerged as a subfield of cancer research. Presumable mechanisms underlying cancer-related neuronal activity (termed neurosciences) include the induction and modulation of signaling pathways that govern cell fate determination and emotional responses (anxiety and stress), such as structural molecules (synaptic structures and current transduction) and secretory substances (neurotransmitters, cytokines, hormones and neuropeptides). In the past 3 years, these neuronal activities, which can either promote cancer growth or be hijacked by cancer cells to support tumor survival and invasion, have been widely demonstrated to be closely related to cancer progression. The molecular mechanisms are also being refined. Despite their great promise, translating neuroscientific discoveries into clinically actionable strategies for cancer diagnosis, prognosis, and treatment remains a formidable task. In this comprehensive review, we attempt to provide a full account of the intersection between neuroscience and cancer research. From the perspective of cancer neuroscience, we fully discuss the potential signaling molecules and their regulatory mechanisms, as well as targets and emerging therapeutic strategies that control tumor progression via multiomics approaches. Overall, cancer neuroscience may have unprecedented potential for understanding neuronal functions and cancer development, ultimately offering the significantly improved cancer treatment.

> **中文摘要：**
> 从神经科学的角度来看，癌症神经科学已成为癌症研究的一个子领域。与癌症相关的神经元活动（被称为神经科学）的假定机制包括诱导和调节控制细胞命运决定和情绪反应（焦虑和压力）的信号通路，例如结构分子（突触结构和电流转导）和分泌物质（神经递质、细胞因子、激素和神经肽）。在过去的3年中，这些既能促进癌症生长，又能被癌细胞劫持以支持肿瘤生存和侵袭的神经元活动，已被广泛证明与癌症进展密切相关。其分子机制也正在得到完善。尽管前景广阔，但将神经科学发现转化为用于癌症诊断、预后和治疗的临床可行策略仍是一项艰巨的任务。在这篇全面的综述中，我们试图对神经科学与癌症研究之间的交叉点进行全面阐述。从癌症神经科学的角度出发，我们充分讨论了潜在的信号分子及其调节机制，以及通过多组学方法控制肿瘤进展的靶点和新兴治疗策略。总之，癌症神经科学在理解神经元功能和癌症发展方面可能具有前所未有的潜力，最终将显著改善癌症治疗。

### 第二部分 AI 大师评价

本文全面综述了癌症神经科学这一新兴交叉学科的最新研究进展，重点探讨了神经系统活动如何通过复杂的信号通路和分泌因子调控肿瘤微环境。作者系统总结了过去三年中发现的神经元与癌细胞互作的分子机制，并结合多组学分析指出了潜在的干预靶点。该综述不仅强调了该领域在揭示癌症发生发展机制中的重要性，也客观指出了从基础研究向临床诊断和治疗转化所面临的巨大挑战，为未来的整合治疗策略提供了重要指引。

---

## 7. 甲状旁腺激素相关蛋白是特发性肺纤维化的一个治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41724741)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41724741
**DOI：** 10.1038/s41392-026-02578-8

### 第一部分 原文与翻译

**英文原标题：** Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis.

> **英文摘要：**
> The crosstalk between immune or alveolar epithelial cells and fibroblasts mediated by paracrine signaling molecules is associated with the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, studies investigating the active involvement of soluble mediators derived from bronchial epithelial cells in fibroblast activation and the development of pulmonary fibrosis are limited. Reanalysis of bulk and single-cell RNA-sequencing data from human bronchus and IPF lung tissue revealed marked upregulation of parathyroid hormone-like hormone (PTHLH) in IPF lung tissue compared with normal tissue, with expression predominantly localized to bronchial epithelial cells. parathyroid hormone-related protein (PTHrP) translated from PTHLH was significantly increased in the bronchial epithelium of IPF patients and bleomycin-induced pulmonary fibrosis mice. Furthermore, the paracrine peptide PTHrP, generated through post-translational processing of PTHrP, was elevated in lung homogenates and bronchoalveolar lavage fluid obtained from fibrotic lungs. Cell- and animal-based experiments showed that PTHrP activated fibroblasts and extracellular matrix production, resulting in the progression of pulmonary fibrosis. In a preclinical evaluation using a bleomycin-induced pulmonary fibrosis mouse model, attenuating effects against pulmonary fibrosis were observed using neutralizing antibodies, peptides, and gene silencing strategies targeting the PTHrP/parathyroid hormone 1 receptor axis. In conclusion, our results suggest that PTHrP derived from bronchial epithelial cells is involved in the pathogenesis of IPF and is a promising target for alleviating disease progression.

> **中文摘要：**
> 由旁分泌信号分子介导的免疫或肺泡上皮细胞与成纤维细胞之间的串扰与特发性肺纤维化（IPF）的发病机制有关。然而，关于支气管上皮细胞来源的可溶性介质在成纤维细胞激活和肺纤维化发展中的主动参与作用的研究还很有限。通过对人类支气管和IPF肺组织的体转录组和单细胞RNA测序数据的重新分析，发现与正常组织相比，IPF肺组织中的甲状旁腺激素样激素（PTHLH）显著上调，且其表达主要定位于支气管上皮细胞。由PTHLH翻译而来的甲状旁腺激素相关蛋白（PTHrP）在IPF患者和博来霉素诱导的肺纤维化小鼠的支气管上皮中显著增加。此外，通过PTHrP翻译后加工产生的旁分泌肽PTHrP在纤维化肺的肺匀浆和支气管肺泡灌洗液中水平也有所升高。细胞和动物实验表明，PTHrP激活了成纤维细胞并促进了细胞外基质的产生，从而导致肺纤维化的进展。在利用博来霉素诱导的肺纤维化小鼠模型进行的临床前评估中，通过靶向PTHrP/甲状旁腺激素1受体（PTH1R）轴的中和抗体、多肽和基因沉默策略，观察到了对肺纤维化的缓解作用。总之，我们的研究结果表明，源自支气管上皮细胞的PTHrP参与了IPF的发病过程，是缓解疾病进展的一个有前途的靶点。

### 第二部分 AI 大师评价

本研究通过整合单细胞转录组学分析与多项实验验证，系统揭示了支气管上皮细胞来源的PTHrP在特发性肺纤维化（IPF）中的核心作用。研究不仅明确了PTHrP通过旁分泌途径激活成纤维细胞及促进细胞外基质沉积的病理机制，还通过中和抗体和基因沉默等多种手段，在临床前模型中证实了干预PTHrP/PTH1R轴的治疗有效性。该发现为IPF的靶向药物研发提供了重要的新候选分子，具有较高的临床转化潜力。

---

速递结束，祝您工作愉快！